H.R. 8794 — FED UP with Bleeding Disorders Act of 2026

This section states findings that as many as 1 percent of women in the United States may have a bleeding disorder, with diagnosis delays of 16 years or more; that care at hemophilia treatment centers reduces mortality and hospitalization rates by 40 percent; that women with bleeding disorders face higher risks of adverse pregnancy outcomes and unnecessary hysterectomies; and that heavy menstrual bleeding imposes $1 billion in direct and $12 billion in indirect annual economic costs.

This section directs the Secretary of Health and Human Services to review and update as needed Federal programs, activities, and strategic plans on bleeding disorders in women and girls, covering the state of the science, provider training and education, access to treatment at hemophilia treatment centers and other settings including rural and underserved areas, and inclusion in clinical research. The Secretary must submit a report with findings and recommendations on improvements and interagency coordination to the House Energy and Commerce and Appropriations Committees and the Senate HELP and Appropriations Committees within two years, post the report publicly, and solicit comments from patients, advocacy organizations, and federally funded researchers. It defines bleeding disorder as an inheritable clotting impairment, including hemophilia and von Willebrand disease.

This section directs the Secretary to award competitive grants or contracts, within one year after the report under section 3, for a national evidence-based education and awareness campaign on bleeding disorders in women and girls. The campaign must target women and girls plus specified providers, reach rural and underserved areas, include culturally and linguistically appropriate resources, and undergo evaluation with a report to Congress; it authorizes $10 million annually for fiscal years 2027 through 2031.